Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicinePembrolizumab for Early Triple-Negative Breast Cancer

Early triple-negative breast cancer patients who received pembrolizumab along with neoadjuvant chemotherapy had a significantly higher rate of pathological complete responses than those who received placebo along with neoadjuvant chemotherapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form